Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Study Uncovers Mechanism Behind Cognitive Impairment in Chemotherapy Patients



Researchers at the University of Kansas have now identified the potential mechanism behind this side effect – commonly referred to as “chemo brain” – and may have even identified some new ways to treat and prevent it.

Share this!

April 18, 2017 | by Sarah Hand, M.Sc.

While chemotherapy remains one of the most common types of cancer treatment, it can have a number of serious side effects, including cognitive impairments. Researchers at the University of Kansas have now identified the potential mechanism behind this side effect – commonly referred to as “chemo brain” – and may have even identified some new ways to treat and prevent it.

“[Chemo brain is] something doctors learned about because patients were complaining,” said Dr. Michael A. Johnson, associate professor in the department of chemistry at the University of Kansas. “Symptoms include visual and verbal memory loss, so if you have a conversation with somebody, you may have difficulty recalling it. You might have attention deficit, so if you are trying to do taxes, it might be difficult to focus. It also can result in a decline in processing speed, so it may be more difficult to think on your toes. You may have trouble remembering words.”

Johnson and his colleagues found that 5-Fluorouracil – a chemotherapy agent commonly used to treat cancers, including breast, colorectal and pancreatic – can have a damaging effect on the myelin sheath that protects nerve cells in the brain. The researchers noted that this myelin damage translated to neurodegenerative symptoms in an area of the brain responsible for learning and memory, known as the hippocampus.

The researchers also found that treatment with chemotherapy was associated with elevated levels of hydrogen peroxide in the brains of mice. When these animals were treated with an experimental compound known as KU-32, the negative effects of hydrogen peroxide and the cognitive decline associated with chemotherapy treatment were mitigated.

“In our preliminary results, we found that hydrogen peroxide temporarily increases in the brains of chemotherapy-treated rats,” said Johnson, whose paper was published in the journal, Behavioural Brain Research. “Because hydrogen peroxide is a reactive oxygen species and potentially damaging, it may have an effect on cognitive function.

“Additionally, we may have a therapy that can serve as a preventative in order to treat it. We found that KU-32 prevents cognitive impairment, and our preliminary neurochemical data suggest that it may prevent increases in hydrogen peroxide production.”

The results of this study could help physicians treat the symptoms of chemo brain in the future. More preclinical data on KU-32 will need to be collected before the drug can be tested in human patients.

Keywords:  Cognitive Impairment, Chemotherapy, Cancer


Share this with your colleagues!

Canadian Regulator Recalls Pie Shells Over E. Coli Contaminated Flour

April 28, 2017 - Multiple brands of pie and tart shells are being recalled in Canada after the flour used to manufacture them was linked to 28 cases of illness due to infection with E. coli O121.

Featured In: Food News

FDA Sends Warning Letters to Manufacturers of Fake Cancer Drugs

April 27, 2017 - The FDA is cracking down on the sale of illegal cancer drugs by sending warning letters to 14 US companies selling the unapproved products.

Featured In: Life Science News, Drug Safety News

Womb-Like Device Could Increase Survival of Premature Babies

April 27, 2017 - Researchers at the Children's Hospital of Philadelphia (CHOP) have developed a womb-like device which mimics the environmental conditions found inside the uterus.

Featured In: Life Science News, Medical Device News


What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation


Technology Solutions for Late Phase Research: Optimising Real World Data Assets

Serialization for Late Starters – With Live Industry Research Results

Clinical Not All Antioxidants Are Created Equal: Astaxanthin, The Antioxidant Powerhouse

The New Gold Standards of IRT Delivery for Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.